Overview
TB-500 demonstrates remarkable resistance to proteolytic degradation and maintains activity across various physiological pH ranges, contributing to its therapeutic potential. The peptide exhibits high systemic bioavailability via subcutaneous injection and distributes widely to tissues with high metabolic activity and injury sites.
Chemical structure & Properties
Molecular Formula: C212H350N56O78S
Molecular Weight: 4,963 Da
Sequence: 43 amino acids with N-terminal acetylation
Half-life: Approximately 2.5-3 hours following subcutaneous administration
Stability: Stable at room temperature in lyophilized form, requires refrigeration when reconstituted
Regulatory Status and
Legal Considerations
FDA Status
Classification: Previously listed as Category 2. Nominated but withdrawn as of April 22, 2026
Approval Status: Not approved for human therapeutic use in any indication
Compounding: Standard 503A/503B pharmacy regulations now apply. Consult current FDA guidance before compounding.
Regulatory Position: Insufficient evidence for safety and efficacy determination
WADA Status
Classification: Prohibited under S0: Non-Approved Substances category
Athletic Use: Banned in competitive sports and subject to anti-doping penalties
Testing: Detectable in anti-doping screening protocols and enforcement testing
Legal Availability
Commercial Status: Not legally available as FDA-approved prescription medication
Market Presence: Available through research chemical suppliers without regulatory oversight
Quality Control: No regulatory oversight for purity, potency, or sterility standards
Clinical Use: Limited to research institutions and experimental protocols under appropriate oversight
The Paragon Method: Step-by-Step
Clinical Considerations
Important Guidelines:
No FDA-approved dosing guidelines exist for human therapeutic use
Individual response variability significant requiring personalized approach
Medical supervision essential for any therapeutic application or research use
Quality and purity of commercially available products not guaranteed or regulated
Priority Research Areas
Clinical Development:
Large-scale randomized controlled trials for safety and efficacy determination
Standardized dosing protocols for various clinical applications and patient populations
Long-term safety studies including carcinogenicity and reproductive toxicity assessment
Biomarker development for treatment response prediction and monitoring
Mechanistic Studies:
Detailed characterization of actin regulation and cellular migration mechanisms
Investigation of optimal combination therapy protocols with other regenerative treatments
Drug interaction studies with commonly prescribed medications
Precision medicine approaches based on individual patient characteristics
Emerging Applications
Research is investigating potential applications in:
Traumatic brain injury recovery and neuroprotection
Stroke rehabilitation and neurological recovery enhancement
Neurodegenerative disease modification and progression slowing
Ophthalmological applications including corneal wound healing and retinal disorders
Aesthetic medicine applications for cosmetic wound healing and anti-aging
Conclusion
TB-500 represents a promising therapeutic peptide with demonstrated preclinical efficacy in tissue repair, wound healing, and inflammatory modulation through its unique actin regulation mechanism. Its ability to enhance cellular migration, reduce inflammation, and promote tissue regeneration offers potential advantages in regenerative medicine applications. However, the current evidence base remains predominantly preclinical, with limited human clinical data available.
The absence of FDA approval, regulatory restrictions, and potential safety considerations necessitate careful evaluation and medical supervision for any therapeutic application. The theoretical risk of enhanced angiogenesis in malignant conditions requires particular caution in patient selection and ongoing monitoring protocols.
Healthcare providers considering TB-500 therapy should engage in comprehensive risk-benefit discussions with patients, exploring evidence-based alternatives where available. Future large-scale clinical trials will be essential in establishing safety profiles, optimal dosing regimens, and specific clinical indications for TB-500 in human medicine. Until comprehensive clinical evidence is available, its use should remain limited to research settings and experimental protocols under appropriate medical oversight.
TB-500 SCIENTIFIC
DATA SUMMARY
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
4,963 Da
43 residues
~2.5-3 hours (subcutaneous)
High SC, wide tissue distribution
Up to 12 hours (plasma)
Application
Wound Healing
Muscle Recovery
Tendon/Ligament
Cardiovascular
Studies
25+ studies
20+ studies
15+ studies
12+ studies
Dose Range
0.25-5 mg
2-5 mg weekly
1-3 mg weekly
2-10 mg
Outcome
Accelerated closure, enhanced re-epithelialization
Enhanced regeneration, reduced fibrosis
Improved healing, reduced adhesions
Improved LV function, reduced infarct size
Study Type
Case Series
Athletic Recovery
Chronic Wounds
Population
Small patient cohorts
Athletes with soft tissue injuries
Limited patient series
Results
Improved wound healing reported
Enhanced recovery, improved mobility
Accelerated healing in difficult cases
Limitations
Anecdotal reports, no controls
Subjective assessments only
No standardized outcome measures
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
No toxicity up to 20 mg/kg tested
No organ-specific toxicity in chronic studies
Minimal: rare injection site reactions
Limited human data available
Authority
FDA
WADA
DEA
Classification
Nominated but Withdrawn (4/22/2026)
Prohibited Substance
Unscheduled
Status
Not approved for human use
Banned in competitive sports
Not controlled substance
Peptides work best as one part of a complete, medically supervised plan. Many patients pair these with our regenerative treatments, including PRP and bone marrow concentrate (BMAC). To see how this fits your goals, explore our full approach to peptide therapy in Atlanta.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. TB-500 is not approved by the FDA for human therapeutic use. Healthcare providers and patients should consult current regulatory guidelines and conduct thorough risk-benefit analyses before considering any peptide therapy.
The content reflects current scientific literature and regulatory status as of April 22–23, 2026
Explore Peptide Therapy at Paragon
Peptides work best as part of a bigger plan, not on their own. At Paragon Sports Medicine in Atlanta, every peptide is prescribed by our team, guided by your labs and your goals, and matched to the right protocol for you. If you are wondering whether this one fits where you want to go, our peptide therapy program in Atlanta is the place to start.